24
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Chromatographic analysis of tryptophan metabolites

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The kynurenine pathway generates multiple tryptophan metabolites called collectively kynurenines and leads to formation of the enzyme cofactor nicotinamide adenine dinucleotide. The first step in this pathway is tryptophan degradation, initiated by the rate‐limiting enzymes indoleamine 2,3‐dioxygenase, or tryptophan 2,3‐dioxygenase, depending on the tissue. The balanced kynurenine metabolism, which has been a subject of multiple studies in last decades, plays an important role in several physiological and pathological conditions such as infections, autoimmunity, neurological disorders, cancer, cataracts, as well as pregnancy. Understanding the regulation of tryptophan depletion provide novel diagnostic and treatment opportunities, however it requires reliable methods for quantification of kynurenines in biological samples with complex composition (body fluids, tissues, or cells). Trace concentrations, interference of sample components, and instability of some tryptophan metabolites need to be addressed using analytical methods. The novel separation approaches and optimized extraction protocols help to overcome difficulties in analyzing kynurenines within the complex tissue material. Recent developments in chromatography coupled with mass spectrometry provide new opportunity for quantification of tryptophan and its degradation products in various biological samples. In this review, we present current accomplishments in the chromatographic methodologies proposed for detection of tryptophan metabolites and provide a guide for choosing the optimal approach.

          Related collections

          Most cited references146

          • Record: found
          • Abstract: found
          • Article: not found

          Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion.

          Tryptophan catabolism in cancer is increasingly being recognized as an important microenvironmental factor that suppresses antitumor immune responses. It has been proposed that the essential amino acid tryptophan is catabolized in the tumor tissue by the rate-limiting enzyme indoleamine-2,3-dioxygenase (IDO) expressed in tumor cells or antigen-presenting cells. This metabolic pathway creates an immunosuppressive milieu in tumors and in tumor-draining lymph nodes by inducing T-cell anergy and apoptosis through depletion of tryptophan and accumulation of immunosuppressive tryptophan catabolites. Competitive inhibitors of IDO are currently being tested in clinical trials in patients with solid cancer, with the aim of enhancing the efficacy of conventional chemotherapy. There are, however, certain tumor types that are capable of catabolizing tryptophan but are largely IDO-negative. Recent evidence from studies in malignant gliomas and other types of cancers points to alternative enzymatic pathways of tryptophan catabolism involving tryptophan-2,3-dioxygenase (TDO). TDO, which is considered responsible for regulating systemic tryptophan levels in the liver, is constitutively expressed in some cancers and is equally capable of suppressing antitumor immune responses. Depletion of tryptophan induces signaling events in T cells, leading to anergy and apoptosis; however, active immunomodulation by accumulating tryptophan catabolites, most notably kynurenine, appears to play an equally important role. These immunomodulatory effects of kynurenine are mediated by the aryl hydrocarbon receptor. This intracellular transcription factor has classically been viewed as a receptor for environmental toxins, such as dioxin, and its important role in influencing immune responses, especially in epithelial barriers, is only beginning to emerge. This review summarizes the exciting developments in our understanding of tryptophan catabolism as a key factor in the immunobiology of cancer. ©2012 AACR.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase.

            Tryptophan catabolism mediated by indoleamine 2,3-dioxygenase (IDO1) is an important mechanism of peripheral immune tolerance contributing to tumoral immune resistance, and IDO1 inhibition is an active area of drug development. Tryptophan 2,3-dioxygenase (TDO) is an unrelated hepatic enzyme that also degrades tryptophan along the kynurenine pathway. Here, we show that enzymatically active TDO is expressed in a significant proportion of human tumors. In a preclinical model, TDO expression by tumors prevented their rejection by immunized mice. We developed a TDO inhibitor, which, upon systemic treatment, restored the ability of mice to reject TDO-expressing tumors. Our results describe a mechanism of tumoral immune resistance based on TDO expression and establish proof-of-concept for the use of TDO inhibitors in cancer therapy.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Targeting the indoleamine 2,3-dioxygenase pathway in cancer

              Tumor cells escape the immune surveillance system of the host through a process called immune tolerance. Immunotherapy targets molecules that serve as checks and balances in the regulation of immune response. Indoleamine-2,3-dioxygenase (IDO) is an intracellular enzyme, which through the process of tryptophan depletion exerts an immunosuppressive effect, facilitating immune escape of tumors. This review summarizes our current knowledge on IDO expression in malignancies, the IDO inhibitors that are currently available and those under clinical development.
                Bookmark

                Author and article information

                Contributors
                staniszkul@kul.lublin.pl
                Journal
                J Sep Sci
                J Sep Sci
                10.1002/(ISSN)1615-9314
                JSSC
                Journal of Separation Science
                John Wiley and Sons Inc. (Hoboken )
                1615-9306
                1615-9314
                26 June 2017
                August 2017
                : 40
                : 15 ( doiID: 10.1002/jssc.v40.15 )
                : 3020-3045
                Affiliations
                [ 1 ] Laboratory of Separation and Spectroscopic Method Applications, Centre for Interdisciplinary Research The John Paul II Catholic University of Lublin Lublin Poland
                [ 2 ] Laboratory of Medical Microbiology Hirszfeld Institute of Immunology and Experimental Therapy Polish Academy of Sciences Wroclaw Poland
                [ 3 ] Department of Medical Biochemistry Wroclaw Medical University Wroclaw Poland
                Author notes
                [*] [* ] Correspondence

                Dr. Magdalena Maria Staniszewska, Laboratory of Separation and Spectroscopic Method Applications, Centre for Interdisciplinary Research, The John Paul II Catholic University of Lublin, Lublin, Poland.

                Email: staniszkul@ 123456kul.lublin.pl

                Author information
                http://orcid.org/0000-0003-1119-2397
                Article
                JSSC5515
                10.1002/jssc.201700184
                5575536
                28590049
                5fc3880b-e2ce-4b0d-8ded-de2afe5ea0a6
                © 2017 The Authors. Journal of Separation Science published by Wiley‐VCH Verlag GmbH & Co. KGaA, Weinheim

                This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

                History
                : 16 February 2017
                : 15 May 2017
                : 24 May 2017
                Page count
                Figures: 2, Tables: 6, Pages: 26, Words: 15149
                Funding
                Funded by: Operational Programme Development of Eastern Poland 2007–2013
                Award ID: POPW.01.03.00‐06‐003/09‐00
                Funded by: The Leading National Research Centre (KNOW) for years 2014‐2018
                Award ID: 42/2016/KNOW/IITD
                Categories
                Review Article
                Liquid Chromatography
                Custom metadata
                2.0
                jssc5515
                August 2017
                Converter:WILEY_ML3GV2_TO_NLMPMC version:5.1.8 mode:remove_FC converted:30.08.2017

                chromatography,kynurenines,kynurenine pathway,tryptophan metabolites,tissue analysis

                Comments

                Comment on this article